Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Bioavailability of AZD5004 in Healthy Men
NCT06857695Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elecoglipron in type 2 diabetes mellitus (T2DM) and obesity, sponsored by AstraZeneca. Primary endpoints: Absolute bioavailability, Amount of AZD5004 excreted and 3 more. Started Mar 2025; status: completed.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06857695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857695.